1

Coloplast

Coloplast
Leadership team

Mr. Anders Lonning-Skovgaard (Exec. VP & CFO)

Mr. Allan Rasmussen (Exec. VP of Global Operations)

Products/ Services
Biotechnology, Health Care, Manufacturing, Medical
Number of Employees
1,000 - 20,000
Headquarters
Minneapolis, Minnesota, United States
Established
1978
Company Registration
SEC CIK number: 0001294325
Net Income
500M - 1B
Revenue
Above - 1B
Overview
Location
Summary

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates in three segments: Chronic Care, Interventional Urology, and Wound & Skin Care. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include bathing and cleansing products, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.

History

Coloplast was founded in 1957 by Aage Louis-Hansen. His son Niels Peter Louis-Hansen owns 20% of the company and is deputy chairman. It employs more than 12,000 people and operates around the world, with sales activities in 53 countries and production in Denmark, Hungary, France, China and the US. It has its global headquarters in Humlebæk, Denmark. Its United States operations and North American headquarters are based in Minneapolis, Minnesota. The company manufactures and supplies products to hospitals and institutions, as well as wholesalers and retailers. In selected markets, Coloplast is a direct supplier to consumers.

The company had revenues of DKK 18.554 billion in 2020/2021. Europe constitutes the biggest market with 63% of sales, while 22% of sales are in North America and 15% in the rest of the world. Coloplast is listed on the Danish Stock Exchange, and has for a number of years been represented among the 20 most traded shares in the country.In 2016, Coloplast was listed as the 22nd most innovative company in the world by Forbes Forbes. In 2015, Coloplast was listed as the 33rd most innovative company in the world by Forbes Magazine. The company has been featured in The Star Tribune's annual list of top employers in Minnesota.In November 2021, Coloplast announces the acquisition for 2.5 billion dollars of Atos Medical, specialized in laryngectomy, which belonged to PAI Partners.

Mission

Making life easier for people with intimate healthcare needs

Vision

Setting the global standard for listening and responding

Key Team

Mr. Nicolai Buhl Andersen (Exec. VP of Innovation)

Mr. Paul Marcun (Exec. VP of Growth)

Mr. Rasmus Hannemann Møller (Sr. VP of Wound & Skin Care)

Mr. Thomas Barfod (Sr. Controller & Employees Representative Director)

Ellen Bjurgert (VP of Investor Relations)

Dennis Kaysen (Director of Corp. Communications)

Dorthe Ronnau (Sr. VP of People & Culture)

References
Coloplast
Leadership team

Mr. Anders Lonning-Skovgaard (Exec. VP & CFO)

Mr. Allan Rasmussen (Exec. VP of Global Operations)

Products/ Services
Biotechnology, Health Care, Manufacturing, Medical
Number of Employees
1,000 - 20,000
Headquarters
Minneapolis, Minnesota, United States
Established
1978
Company Registration
SEC CIK number: 0001294325
Net Income
500M - 1B
Revenue
Above - 1B